HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.

AbstractBACKGROUND:
2,5-Dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib (Celebrex) that lacks COX-2-inhibitory function. However, despite its inability to block COX-2 activity, DMC is able to potently mimic the anti-tumor effects of celecoxib in vitro and in vivo, indicating that both of these drugs are able to involve targets other than COX-2 to exert their recognized cytotoxic effects. However, the molecular components that are involved in mediating these drugs' apoptosis-stimulatory consequences are incompletely understood.
RESULTS:
We present evidence that celecoxib and DMC are able to down-regulate the expression of survivin, an anti-apoptotic protein that is highly expressed in tumor cells and known to confer resistance of such cells to anti-cancer treatments. Suppression of survivin is specific to these two drugs, as other coxibs (valdecoxib, rofecoxib) or traditional NSAIDs (flurbiprofen, indomethacin, sulindac) do not affect survivin expression at similar concentrations. The extent of survivin down-regulation by celecoxib and DMC in different tumor cell lines is somewhat variable, but closely correlates with the degree of drug-induced growth inhibition and apoptosis. When combined with irinotecan, a widely used anticancer drug, celecoxib and DMC greatly enhance the cytotoxic effects of this drug, in keeping with a model that suppression of survivin may be beneficial to sensitize cancer cells to chemotherapy. Remarkably, these effects are not restricted to in vitro conditions, but also take place in tumors from drug-treated animals, where both drugs similarly repress survivin, induce apoptosis, and inhibit tumor growth in vivo.
CONCLUSION:
In consideration of survivin's recognized role as a custodian of tumor cell survival, our results suggest that celecoxib and DMC might exert their cytotoxic anti-tumor effects at least in part via the down-regulation of survivin - in a manner that does not require the inhibition of cyclooxygenase-2. Because inhibition of COX-2 appears to be negligible, it might be worthwhile to further evaluate DMC's potential as a non-coxib alternative to celecoxib for anti-cancer purposes.
AuthorsPeter Pyrko, Nathaniel Soriano, Adel Kardosh, Yen-Ting Liu, Jasim Uddin, Nicos A Petasis, Florence M Hofman, Ching-Shih Chen, Thomas C Chen, Axel H Schönthal
JournalMolecular cancer (Mol Cancer) Vol. 5 Pg. 19 (May 18 2006) ISSN: 1476-4598 [Electronic] England
PMID16707021 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2,5-dimethylcelecoxib
  • Antineoplastic Agents
  • BIRC5 protein, human
  • Inhibitor of Apoptosis Proteins
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Pyrazoles
  • Sulfonamides
  • Survivin
  • Irinotecan
  • Celecoxib
  • Camptothecin
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Apoptosis (drug effects)
  • Camptothecin (analogs & derivatives, pharmacology)
  • Celecoxib
  • Cell Survival (drug effects)
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Gene Expression Regulation (drug effects)
  • HCT116 Cells
  • Humans
  • Inhibitor of Apoptosis Proteins
  • Irinotecan
  • Male
  • Mice
  • Mice, Nude
  • Microtubule-Associated Proteins (genetics, metabolism)
  • Neoplasm Proteins (genetics, metabolism)
  • Neuroblastoma (drug therapy, pathology)
  • Promoter Regions, Genetic (genetics)
  • Pyrazoles (pharmacology, therapeutic use)
  • Sulfonamides (pharmacology, therapeutic use)
  • Survivin
  • Transcription, Genetic
  • Transfection
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: